Milestone Pharmaceuticals Inc.

MIST

Milestone Pharmaceuticals Inc.

MIST

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-04-16Shares Purchased (TTM):0Shares Sold (TTM):161,938

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:29,586,561Shares Outstanding:117,794,417Institutional Ownership Pct.:25.12%

Earnings Market Reaction:

Filing Date:2026-08-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	170	71	73	47	42	45	25	13	13	10	14	10
Short Term Investments	1	113	33	36	1	11	44	64	70	79	52	66
Accounts Receivable Net Current	3	2	-	-	-	-	-	-	-	-	-	-
Assets Current
Assets Current	180	192	112	87	46	60	74	81	87	94	73	85
Prepaid Expense Current	1	1	2	3	1	2	2	3	2	2	3	7
Inventory Net	5	2	1	-	-	-	-	-	-	-	-	-
Other Receivables Net Current	1	1	2	1	1	1	1	1	2	1	3	2
Operating Lease Right Of Use Asset	1	1	1	1	1	1	1	2	2	2	2	2
Property Plant And Equipment Net	0	1	1	0	0	0	0	0	0	0	0	0
Assets	182	194	114	88	47	62	75	83	89	96	75	87
Liabilities And Stockhold…
Liabilities
Accounts Payable And Accrued Liabilities Current	-	-	13	10	9	12	8	5	4	4	7	8
Accounts Payable Current	8	10	-	-	-	-	-	-	-	-	-	-
Accrued Liabilities Current	12	10	-	-	-	-	-	-	-	-	-	-
Liabilities Current
Liabilities Current	22	21	14	11	9	13	8	5	5	4	7	8
Operating Lease Liability Current	1	1	1	0	1	1	1	1	1	1	1	1
Deferred Revenue Current	1	0	-	-	-	-	-	-	-	-	-	-
Other Liabilities Current	0	0	0	-	-	-	-	-	-	-	-	-
Operating Lease Liability Noncurrent	0	0	1	1	1	1	1	1	1	1	1	2
Long Term Debt	59	58	57	56	55	54	53	52	52	51	50	49
Other Liabilities Noncurrent	0	0	0	-	-	-	-	-	-	-	-	-
Liabilities	163	158	72	67	65	68	62	59	57	56	58	59
Common Stock Value	385	374	353	312	288	288	288	288	288	288	261	261
Warrants And Rights Outstanding	56	56	56	56	53	53	53	53	53	53	48	48
Stockholders Equity
Additional Paid In Capital	63	63	64	66	42	41	40	38	37	35	34	32
Stockholders Equity	18	36	42	21	-18	-6	13	24	32	40	17	29
Retained Earnings Accumulated Deficit	-485	-457	-431	-413	-401	-388	-368	-355	-346	-336	-326	-312
Liabilities And Stockholders Equity	182	194	114	88	47	62	75	83	89	96	75	87
Common Stock No Par Value	-	-	0	-	-	-	0	-	-	-	-	-
Common Stock Par Or Stated Value Per Share	0	0	-	0	0	0	0	0	0	0	0	0
Common Stock Shares Issued	124	118	106	85	53	53	53	53	53	53	33	33
Shares Outstanding	124	118	106	85	53	53	53	53	53	53	33	33
Class Of Warrant Or Right Issued	-	16	16	-	-	13	13	-	-	13	10	-
Class Of Warrant Or Right Outstanding	16	16	16	16	13	13	13	13	13	13	10	10

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-28.49%	-23.26%	-35.47%	-	-	-	-	-	-	-	-	-
2025	47.86%	65.81%	22.22%	8.43%	27.11%	15.66%	38.86%	6.22%	-1.04%	48.53%	41.18%	-9.56%
2024	-14.12%	-21.76%	-21.18%	0.71%	8.51%	2.13%	-0.53%	17.65%	5.35%	-65.71%	-35.47%	-20.20%
2023	-	-	-	-	-	-	26.07%	-26.50%	-30.34%	10.90%	8.97%	-6.41%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	8.13	9.18	8.01	8.24	4.97	4.67	9.10	15.40	19.13	22.75	10.11	10.45
Quick Ratio	7.87	9.03	7.83	7.99	4.89	4.48	8.87	14.92	18.75	22.18	9.67	9.59
Working Capital	158.14M	171.31M	97.94M	76.15M	36.89M	47.51M	65.80M	75.73M	82.79M	89.84M	65.81M	76.68M
Leverage & Debt
Debt to Equity	8.97	4.37	1.72	3.28	-3.67	-11.11	4.74	2.44	1.79	1.40	3.49	2.06
Interest Coverage TTM	-7.25	-9.28	-16.19	-15.17	-14.84	-14.31	-11.76	-12.37	-14.25	-16.53	-23.92	-26.83
Debt Ratio	0.90	0.81	0.63	0.77	1.37	1.10	0.83	0.71	0.64	0.58	0.78	0.67
Efficiency & Turnover
Asset Turnover TTM	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding TTM	1,245.67	2,461.45	-	-	-	-	-	-	-	-	-	-
Receivables Turnover TTM	0.29	0.15	-	-	-	-	-	-	-	-	-	-
Per Share Metrics
Free Cash Flow Per Share TTM	-0.48	-0.44	-0.46	-0.34	-0.49	-0.63	-0.54	-0.60	-0.69	-0.78	-1.39	-1.48
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-9,834.25%	-27,428.57%	-	-	-	-	-	-	-	-	-	-
Net Profit Margin TTM	-10,540.90%	-28,723.95%	-	-	-	-	-	-	-	-	-	-
Growth Metrics
Net Income Growth (1Y)	51.29%	31.65%	51.88%	35.65%	14.71%	-5.74%	-30.44%	-27.82%	-17.57%	-7.15%	2.22%	-4.58%
EPS Growth (1Y)	-34.99%	-40.24%	-23.72%	-15.07%	14.23%	-6.13%	-56.34%	-54.68%	-48.37%	-41.87%	4.67%	-13.40%
Valuation Metrics
P/E TTM	-1.99	-2.05	-3.40	-2.94	-1.87	-0.82	-3.03	-1.90	-1.45	-1.73	-0.94	-1.75
P/B TTM	9.16	3.89	5.14	8.31	-5.85	-6.99	9.58	3.38	2.20	2.39	3.33	3.64
P/S TTM	209.32	588.97	-	-	-	-	-	-	-	-	-	-
Market Cap	166.83M	140.18M	214.60M	170.34M	103.78M	42.77M	125.92M	81.06M	70.32M	95.31M	55.92M	103.79M
Enterprise Value	56.31M	127.05M	198.74M	179.86M	116.52M	51.97M	153.95M	120.69M	108.58M	135.82M	91.93M	142.83M
Calculated Values
Free Cash Flow TTM	-59.54M	-51.48M	-49.34M	-29.19M	-26.46M	-33.91M	-28.88M	-31.84M	-37.00M	-41.57M	-46.57M	-49.71M
Net Debt	-110.52M	-13.13M	-15.86M	9.52M	12.74M	9.20M	28.04M	39.64M	38.27M	40.51M	36.01M	39.04M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-16Sale

Owner: Oliveto, Joseph

Title: President and CEO

Shares: 36,500

Price/Share: $2.26

Value: $82,490.00

Shares Owned: 446,244

Relationship: Director,Officer

Ownership: Direct

2026-01-26Sale

Owner: Muller, Lorenz

Title: Chief Commercial Officer

Shares: 11,180

Price/Share: $1.93

Value: $21,577.40

Shares Owned: 205,406

Relationship: Officer

Ownership: Direct

2026-01-26Sale

Owner: Nelson, Jeffrey Edward

Title: Chief Operating Officer

Shares: 12,245

Price/Share: $1.93

Value: $23,632.85

Shares Owned: 49,848

Relationship: Officer

Ownership: Direct

2026-01-26Sale

Owner: Oliveto, Joseph

Title: President and CEO

Shares: 34,523

Price/Share: $1.93

Value: $66,629.39

Shares Owned: 482,744

Relationship: Director,Officer

Ownership: Direct

2026-01-26Sale

Owner: Bharucha, David

Title: Chief Medical Officer

Shares: 12,245

Price/Share: $1.93

Value: $23,632.85

Shares Owned: 113,181

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-16	Oliveto, Joseph	Director,Officer	President and CEO	Direct	Sale	36,500	2.26	$82,490.00	446,244	4
2026-01-26	Muller, Lorenz	Officer	Chief Commercial Officer	Direct	Sale	11,180	1.93	$21,577.40	205,406	4
2026-01-26	Nelson, Jeffrey Edward	Officer	Chief Operating Officer	Direct	Sale	12,245	1.93	$23,632.85	49,848	4
2026-01-26	Oliveto, Joseph	Director,Officer	President and CEO	Direct	Sale	34,523	1.93	$66,629.39	482,744	4
2026-01-26	Bharucha, David	Officer	Chief Medical Officer	Direct	Sale	12,245	1.93	$23,632.85	113,181	4
2026-01-26	Hasija, Amit	Officer	CFO & EVP of Corp. Development	Direct	Sale	12,245	1.93	$23,632.85	99,848	4
2026-01-08	Oliveto, Joseph	Director,Officer	President and CEO	Direct	Sale	43,000	2.25	$96,750.00	303,721	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

25.12%

Inst. Shares: 29,586,561

Shares Outstanding: 117,794,417

2025-12-31

24.34%

Inst. Shares: 25,860,154

Shares Outstanding: 106,236,344

2025-09-30

39.64%

Inst. Shares: 33,764,243

Shares Outstanding: 85,169,344

2025-06-30

21.95%

Inst. Shares: 11,741,925

Shares Outstanding: 53,494,261

2025-03-31

22.01%

Inst. Shares: 11,767,774

Shares Outstanding: 53,464,273

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	29,586,561	117,794,417	25.12%
2025-12-31	25,860,154	106,236,344	24.34%
2025-09-30	33,764,243	85,169,344	39.64%
2025-06-30	11,741,925	53,494,261	21.95%
2025-03-31	11,767,774	53,464,273	22.01%
2024-12-31	24,476,459	53,353,984	45.88%
2024-09-30	28,663,717	53,327,908	53.75%
2024-06-30	30,163,549	53,269,565	56.62%
2024-03-31	31,320,114	53,245,165	58.82%
2023-12-31	17,464,050	33,483,111	52.16%
2023-09-30	18,538,031	33,481,787	55.37%
2023-06-30	18,651,697	33,363,971	55.90%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Milestone Pharmaceuticals Inc. (MIST) — SEC Financial Statements & Analysis

Milestone Pharmaceuticals Inc. (MIST) is a pharmaceutical preparations company, incorporated in A8. Milestone Pharmaceuticals Inc. trades on Nasdaq as: MIST. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Milestone Pharmaceuticals Inc. reported a Debt-to-Equity ratio of 8.97x, a Price-to-Sales (P/S) ratio of 209.32x (TTM), a Price-to-Book (P/B) ratio of 9.16x (TTM), at a market cap of $166.83M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 8.97x
P/S TTM: 209.32x
P/B TTM: 9.16x
Market Cap: $166.83M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Milestone Pharmaceuticals Inc. in?

Milestone Pharmaceuticals Inc. (MIST) operates in the Pharmaceutical Preparations industry.

What is MIST's market cap?

Milestone Pharmaceuticals Inc. (MIST) has a market capitalization of $166.83M as of 2026-06-30.

What exchange does MIST trade on?

Milestone Pharmaceuticals Inc. (MIST) trades on the Nasdaq.

Where is Milestone Pharmaceuticals Inc. incorporated?

Milestone Pharmaceuticals Inc. is incorporated in Quebec, Canada.